The ASCO Post reports that patients with inflammatory bowel disease who used a GLP-1 receptor agonist had about half the odds of colorectal cancer.
Recap by typeshit. Post by The ASCO Post on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A short fitness clip tagged with Ozempic on the struggle to maintain weight loss. Little detail beyond the title.
Obesity doctor Spencer Nadolsky goes after misconceptions about the triple agonist still in trials. Tap through to see which claims he pushes back on.
Loading…